Home › Compare › BCDAW vs JNJ

BCDAW vs JNJ: Dividend Comparison 2026

BCDAW yields 32786.89% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BCDAW wins by $7.149378406802545e+21M in total portfolio value
10 years
BCDAW
BCDAW
● Live price
32786.89%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.149378406802545e+21M
Annual income
$7,106,739,309,572,423,000,000,000,000.00
Full BCDAW calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — BCDAW vs JNJ

📍 BCDAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCDAWJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCDAW + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BCDAW pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCDAW
Annual income on $10K today (after 15% tax)
$2,786,885.25/yr
After 10yr DRIP, annual income (after tax)
$6,040,728,413,136,559,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, BCDAW beats the other by $6,040,728,413,136,559,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCDAW + JNJ for your $10,000?

BCDAW: 50%JNJ: 50%
100% JNJ50/50100% BCDAW
Portfolio after 10yr
$3.5746892034012726e+21M
Annual income
$3,553,369,654,786,211,600,000,000,000.00/yr
Blended yield
99.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BCDAW
No analyst data
Altman Z
-75.0
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCDAW buys
0
JNJ buys
0
No recent congressional trades found for BCDAW or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCDAWJNJ
Forward yield32786.89% ✓2.14%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$7.149378406802545e+21M$30.5K ✓
Annual income after 10y$7,106,739,309,572,423,000,000,000,000.00 ✓$4,749.88
Total dividends collected$7.146574325368343e+21M$15.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BCDAW vs JNJ ($10,000, DRIP)

YearBCDAW PortfolioBCDAW Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$3,289,389$3,278,688.52$10,594$274.49+$3.28M → BCDAW
2$1,011,452,394$1,007,932,748.46$11,294$360.69+$1011.44M → BCDAW
3$290,735,268,121$289,653,014,059.08$12,133$476.91+$290735.26M → BCDAW
4$78,123,080,869,461$77,811,994,132,571.95$13,156$635.42+$78123080.86M → BCDAW
5$19,624,484,924,633,140$19,540,893,228,102,816.00$14,432$854.61+$19624484924.62M → BCDAW
6$4,608,534,766,328,053,000$4,587,536,567,458,695,700.00$16,056$1,162.76+$4608534766328.04M → BCDAW
7$1,011,770,904,242,838,300,000$1,006,839,772,042,867,400,000.00$18,175$1,604.53+$1011770904242838.25M → BCDAW
8$207,666,224,199,856,750,000,000$206,583,629,332,316,930,000,000.00$21,009$2,252.68+$207666224199856768.00M → BCDAW
9$39,849,623,579,553,230,000,000,000$39,627,420,719,659,375,000,000,000.00$24,911$3,229.73+$39849623579553226752.00M → BCDAW
10$7,149,378,406,802,546,000,000,000,000$7,106,739,309,572,423,000,000,000,000.00$30,458$4,749.88+$7.149378406802545e+21M → BCDAW

BCDAW vs JNJ: Complete Analysis 2026

BCDAW — Stock

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Full BCDAW Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BCDAW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCDAW vs SCHDBCDAW vs JEPIBCDAW vs OBCDAW vs KOBCDAW vs MAINBCDAW vs ABBVBCDAW vs MRKBCDAW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.